Loading stock…

Halozyme Therapeutics, Inc. (HALO) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Halozyme Therapeutics, Inc.

HALOMarket cap $12BPrice $109.7

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops a drug-delivery technology that lets patients get certain cancer and immune therapies via quick injection instead of hours-long IV infusions. Big pharma pays Halozyme royalties to license it, powering blockbuster drugs like Darzalex and Herceptin.

In Bastion Portfolios?

52W Return+64%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+28%10

Revenue Forecast

Rev CAGR (1y)+34%9

Rev CAGR (3y)+17%9

Rev CAGR (5y)+5%5

Earnings Forecast

EPS Growth Y+1+148%10

EPS Growth Y+2+21%8

EPS Growth Y+3+8%6

Quality

Margins

EBIT Margin57%10

Net Income Margin25%8

Free Cash Flow Margin48%10

Debt

Net Debt/EBITDA1.84

Efficiency

ROE174%10

ROA18%10

Earnings Stability77

GEAR+VERY STRONG100

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)118

P/E Ratio (Forward 3y)108

P/BV86.81

EV Multiples

EV/EBITDA Fwd125

EV/EBIT Fwd137

Yield

Free Cash Flow Yield6.5%8

Dividend Yieldna–

Momentum

Short term

1 month return-0%8

3 month return+35%10

YTD return+63%10

Mid term

Price vs 52wHigh94%9

1 year return+66%9

Long term

3 year return+194%9

5 year return+184%9

Risk Shield

Price Risk

Beta0.39

Volatility36%5

Free Cash Flow

Free Cash Flow Margin48%10

Free Cash Flow Yield6.5%8

Quality

ROCE45%10

Earnings Stability77

Net Debt/EBITDA1.84

02Growth

Is it actually growing, and how fast?

HALOHalozyme Therapeutics

Revenue FY25$1.0B

GROWTH RATING↗

STRONG80 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+28%10

Revenue, next 1Y+34%9

Revenue, next 3Y, CAGR+17%9

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+148%10

EPS growth, FY27E+21%8

EPS growth, FY28E+8%6

GROWTH ASSESSMENT

STRENGTHS

It out-grows 80% of companies worldwide.

Revenue grew 28%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 17%/yr over the next 3 years, ahead of most of the market.8/10

Earnings are set to grow in step with sales (EPS about 21%/yr vs revenue 17%/yr).

WATCH

Revenue grew 28%/yr over the last 3 years; forecasts see it cooling to 17%/yr.

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG96 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%8

3-month return+35%10

YTD return+63%10

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+66%9

3-year return+194%9

5-year return+184%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +194% over three years and +184% over five, ahead of 80% of the market.

It's up 66% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+35%) and so far this year (+63%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Halozyme Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

HALOHalozyme Therapeutics

Revenue FY25$1.0B

GROWTH RATING↗

STRONG80 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+28%10

Revenue, next 1Y+34%9

Revenue, next 3Y, CAGR+17%9

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+148%10

EPS growth, FY27E+21%8

EPS growth, FY28E+8%6

GROWTH ASSESSMENT

STRENGTHS

It out-grows 80% of companies worldwide.

Revenue grew 28%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 17%/yr over the next 3 years, ahead of most of the market.8/10

Earnings are set to grow in step with sales (EPS about 21%/yr vs revenue 17%/yr).

WATCH

Revenue grew 28%/yr over the last 3 years; forecasts see it cooling to 17%/yr.

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG96 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%8

3-month return+35%10

YTD return+63%10

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+66%9

3-year return+194%9

5-year return+184%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +194% over three years and +184% over five, ahead of 80% of the market.

It's up 66% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+35%) and so far this year (+63%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Halozyme Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community